Research autopsy programmes in oncology: shared experience from 14 centres across the world
While there is a great clinical need to understand the biology of metastatic cancer in order to treat it more effectively, research is hampered by limited sample availability. Research autopsy programmes can crucially advance the field through synchronous, extensive, and high‐volume sample collectio...
Saved in:
Published in | The Journal of pathology Vol. 263; no. 2; pp. 150 - 165 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.06.2024
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0022-3417 1096-9896 1096-9896 |
DOI | 10.1002/path.6271 |
Cover
Summary: | While there is a great clinical need to understand the biology of metastatic cancer in order to treat it more effectively, research is hampered by limited sample availability. Research autopsy programmes can crucially advance the field through synchronous, extensive, and high‐volume sample collection. However, it remains an underused strategy in translational research. Via an extensive questionnaire, we collected information on the study design, enrolment strategy, study conduct, sample and data management, and challenges and opportunities of research autopsy programmes in oncology worldwide. Fourteen programmes participated in this study. Eight programmes operated 24 h/7 days, resulting in a lower median postmortem interval (time between death and start of the autopsy, 4 h) compared with those operating during working hours (9 h). Most programmes (n = 10) succeeded in collecting all samples within a median of 12 h after death. A large number of tumour sites were sampled during each autopsy (median 15.5 per patient). The median number of samples collected per patient was 58, including different processing methods for tumour samples but also non‐tumour tissues and liquid biopsies. Unique biological insights derived from these samples included metastatic progression, treatment resistance, disease heterogeneity, tumour dormancy, interactions with the tumour micro‐environment, and tumour representation in liquid biopsies. Tumour patient‐derived xenograft (PDX) or organoid (PDO) models were additionally established, allowing for drug discovery and treatment sensitivity assays. Apart from the opportunities and achievements, we also present the challenges related with postmortem sample collections and strategies to overcome them, based on the shared experience of these 14 programmes. Through this work, we hope to increase the transparency of postmortem tissue donation, to encourage and aid the creation of new programmes, and to foster collaborations on these unique sample collections. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. |
---|---|
Bibliography: | These authors contributed equally to this work. Conflict of interest statement: SP is a consultant for AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Eisai, Roche Genetech, and NanoString, and has received research funding awarded to her institution from AbbVie, Pfizer, Lilly, Novartis, Incyte, Covance‐Bayer, AstraZeneca, Genentech, and Medivation. SL receives research funding awarded to her institution from Novartis, Bristol Myers Squibb, MSD, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, and Seattle Genetics. She has acted as a consultant (not compensated) for Seattle Genetics, Novartis, Bristol Myers Squibb, MSD, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics, and Roche‐Genentech. She has also acted as a consultant (paid to institution) for Aduro Biotech, Novartis, GlaxoSmithKline, Roche‐Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, Puma Biotechnology, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, MSD, Amunix, Tallac Therapeutics, Eli Lilly, and Bristol Myers Squibb. CS acknowledges grant support from AstraZeneca, Boehringer‐Ingelheim, BMS, Pfizer, Roche‐Ventana, Invitae (previously Archer Dx, collaboration on minimal residual disease sequencing technologies), Ono Pharmaceutical, and Personalis; is an AstraZeneca advisory board member and chief investigator for the AZ MeRmaiD 1 and 2 clinical trials; and is also co‐chief investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL's scientific advisory board. He receives consultant fees from Achilles Therapeutics (also a scientific advisory board member), Bicycle Therapeutics (also a scientific advisory board member), Genentech, Medicxi, China Innovation Centre of Roche (CICoR; formerly Roche Innovation Centre – Shanghai), Metabomed (until July 2022), and the Sarah Cannon Research Institute; has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, and Roche‐Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021; and currently has stock options in Epic Bioscience and Bicycle Therapeutics, and has stock options and is a co‐founder of Achilles Therapeutics. He is listed as an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and, under his terms of employment, CS is due a revenue share of any revenue generated from such license(s). He holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), and identifying patients who respond to cancer treatment (PCT/GB2018/051912), and a US patent relating to detecting tumour mutations (PCT/US2017/28013) and methods for lung cancer detection (US20190106751A1), and both a European and a US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). He is listed as a co‐inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987) and is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. MJ‐H has received funding from CRUK, NIH National Cancer Institute, IASLC International Lung Cancer Foundation, Lung Cancer Research Foundation, Rosetrees Trust, UKI NETs, and NIHR. MJ‐H has consulted for, and is a member of, the Achilles Therapeutics Scientific Advisory Board and Steering Committee; has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and Bristol Myers Squibb; and is listed as a co‐inventor on a European patent application relating to methods to detect lung cancer (PCT/US2017/028013). This patent has been licensed to commercial entities and, under her terms of employment, MJ‐H is due a share of any revenue generated from such license(s). LT has equity in Alpenglow Biosciences, Inc. TG, MM, JEH, SO, AVL, LM, JMA, MR, HT, LD, DB, SL, ERB, KI, MS, LR, ALW, LG, RMu, PC, AK, CN‐L, HB, LK, CM, MC, AMC, AW, RMe, ZR, LAC, CP, EK, DM, AG, JK, MS, BS, A‐MT, WVDB, GF, and CD declared no conflicts of interest. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0022-3417 1096-9896 1096-9896 |
DOI: | 10.1002/path.6271 |